Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
These therapies are supported by years of clinical research and are administered in a safe, controlled medical environment.
Time-course experiments using phospho-specific antibodies track enhanced FAK activation kinetics under combined treatment conditions
Therefore, ATF4-mediated upregulation of SHMT2 contributes to a higher level of dTTP in T315I-Bcr-Abl-32D cells
Expanding this knowledge will lead to improved genetic risk scores and personalized therapies as new relevant loci are discovered, providing a better picture of the genes and regulatory elements involved in T1D onset and progression
US$ 25.55
US$ 29.24
US$ 20.72
US$ 24.01
US$ 28.08
US$ 28.32
